18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.
about
18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
18FDG-PET/CT and molecular mar ...... minal breast cancers patients.
@en
18FDG-PET/CT and molecular mar ...... minal breast cancers patients.
@nl
type
label
18FDG-PET/CT and molecular mar ...... minal breast cancers patients.
@en
18FDG-PET/CT and molecular mar ...... minal breast cancers patients.
@nl
prefLabel
18FDG-PET/CT and molecular mar ...... minal breast cancers patients.
@en
18FDG-PET/CT and molecular mar ...... minal breast cancers patients.
@nl
P2093
P2860
P356
P1433
P1476
18FDG-PET/CT and molecular mar ...... minal breast cancers patients.
@en
P2093
Brigitte Poirot
Christos Sotiriou
David Groheux
Fatiha A Bouhidel
Jacqueline Lehmann-Che
Lucie Biard
Luis Teixeira
Marc Espié
Matthieu Resche-Rigon
Pascal Merlet
P2860
P304
16343-16353
P356
10.18632/ONCOTARGET.24674
P407
P577
2018-03-27T00:00:00Z